Short description
Massive Bio is an AI powered oncology platform that connects patients to clinical trials while enabling pharma to get access to patients.
Description
Massive Bio, is an Artificial Intelligence (AI) powered platform that connects cancer patients and their treating oncologists to clinical trials while enabling pharmaceutical companies to get access to patients, mostly in community practices, and their information to speed up drug development. Massive Bio combines technology, services and oncology sub-specialist expertise to maximize trial enrollment. Massive Bio is the first company that attacks controlling patient enrollment value chain; Massive Bio does patient identification through direct direct and indirect patient acquisition channels, pre-screening through virtual site, Just-In-Time (JIT) site activation and further analyzes real world data for drug discovery. One of the major differentiating point of Massive Bio is that the Company tackles “last mile” issues for trial enrollment to eliminate site and/or financial considerations of patients. Massive Bio is the go to partner for pharmaceutical companies and CROs to get the right patient at the right time.
Last funding
Cannot Access
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
New York, New York, United States, North America
Founded on
May 4, 2015
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$7890 - 12340
Sign in for full access
Investors
Noaccess, Noaccess, Noway Youcantaccess, Blurry Noaccess, Noway Youcantaccess, Noaccessforu, Noway Youcantaccess, Noway Youcantaccess, Cannot Access, Nopepepe, Nopepepe, Noway Youcantaccess, Noaccess, Absolutely Noaccess, No Way
Sign in for full access
Founders
Arturo Loaiza-Bonilla, Cagatay Culcuoglu, Selin Kurnaz